Sito in Italia dove è possibile acquistare la consegna acquisto Viagra a buon mercato e di alta qualità in ogni parte del mondo.
Galveston county coordinated community clinics
Galveston County Coordinated Community Clinics
Governing Board Meeting
June 1, 2006
Willie Toliver Harlan “Mark” Guidry, MD, MPH (ex-officio)
Upon a motion duly made and seconded, the agenda of June 1, 2006 was unanimously
Upon a motion duly made and seconded, the minutes of April 27, 2006 were
unanimously approved. Excused Absences
Brian Maxwell and Harvey Bazaman were granted excused absences. Item #1 Executive Report
Dr. Guidry presented the Executive report for May 2006. Item #2 Financial Committee Reports
Kathy Barroso, Chief Financial Officer, presented the April 2006 financial report. The
budget revisions were also presented and Virginia Valentino made a motion to approve
the budget revisions, Dr. Howard seconded, and the motion was carried unanimously.
Kathy Barroso also presented the audit engagement letter from Null-Lairson. The board
unanimously approved the letter, and Mary McCall, on behalf of Brian Maxwell, will
sign it. The new dental fees were presented to the board. Dr. Howard made a motion
that the dental fees be approved with an exception that the guidelines be changed.
Virginia Valentino seconded, and the motion was carried unanimously. Item #3 Approval of Updated Policies
Jay Holland, Chief Operating Officer, presented the policies enclosed in the mail out.
Upon a motion made by Dr. Howard and seconded by Dorothy Goodman, the policies
were unanimously approved.
Item #4 Approval of UTMB OB/GYN Glyburide Research
Pam Jahnke, Strategic Plan Evaluator, presented a request from UTMB to enlist 4C’s
patients for this research project. Upon a motion made by Dr. Howard and seconded by
Virginia Valentino, the approval of the Glyburide research was unanimously approved. Item #5 Evening Clinic Proposal
Patrick Butler, 4C’s Business Manager, provided the Board three options for the evening
clinics. The Board unanimously approved recommendation #2, which is Monday and
Wednesday, one provider to see Pedi only, one provider to see all scheduled patients, and
one provider to see walk-ins only. Tuesday and Thursdays will have one provider to see
all scheduled patients and one provider to see walk-ins only. Item #6 Privileging and Re-privileging
Pam Jahnke, Strategic Plan Evaluator, presented the recommendation from the Dental
Director to privilege Barbara Scott, DDS and to re-privilege Michael McRaith, DDS.
Upon a motion duly made and seconded, the privileging and re-privileging was
unanimously approved. Item #7 Discussion of Pharmacy Services
Patrick Butler, 4C’s Business Manager, presented a list of concerns regarding the
Pharmacy. This was discussed and Patrick will keep the Board apprised of the situation.
Item #8 Access to Care and Customer Service Survey
Pam Jahnke, Strategic Plan Evaluator, presented the quarterly access to care measures
and the customer service survey. Item #9 Informational Reports
The Board received the informational reports as circulated. Item #10 Executive Session – Medical Staffing Proposal
The Board entered executive session at 12:55 p.m. The Board ended executive session at
1:03 p.m. Upon entering open session again, Dr. Howard made a motion that the Board
approve the executive recommendations to use current salary savings to adjust the budget
to increase midlevel pay. Willie Toliver seconded, and the motion was carried
unanimously. Executive staff will monitor budgets and services on a monthly basis and
keep the Board informed. Only if necessary will staff return to this Board to reconsider
allocating reserve dollars. In this case, the Provider will be given a notice of the
organization’s intent to evaluate the staff needs for the level of pediatric services
provided in the 4C’s clinic and will make a decision within the next year about whether
or not it is in the best interest of the 4C’s clinic to continue employing said Provider.
Data will be collected and presented to the Board for determination. Adjournment
Upon a motion duly made and seconded, the Board adjourned at 1:05 p.m.
∂ÈÌ¤ÏÂÈ·: ÕÏ. ¶·‡ÏÔ˘1, ¡. √ÈÎÔÓÔÌ¿ÎË˜2, £. ¶·Ó·Óﬁ˜3, º. ¶ÂÙ˙ÂÚ›‰Ë4, ™. ¶¤ÙÚÔ‚·5 1Managing Partner BIONOVA, 2Consultant Bio Business Analysis Unit, 3Consultant technology transfer Unit and alernate NCP, 4Pharmacology Consultant 5Science Editor Advanced Cell Technology Completes Acquisition of Mytogen, Inc. lead to a significant
Update on Rosiglitazone Safety Concerns On May 21, 2007, the New England Journal of Medicine published a meta-analysis online that found an increased risk of myocardial infarction (MI) associated with the use of rosiglitazone (odds ratio 1.43; 95% confidence interval [CI], 1.03-1.98; p=0.03).1 Since then, other information has been published, including an interim analysis of data from th